C hronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the world, and a major cause of chronic morbidity. 1 Unfortunately, clinicians cannot currently offer treatments to most COPD patients that will favorably change the course of this highly prevalent condition. Therefore, the goal of clinical management is to improve patients' health-related quality of life (HRQoL) by relieving symptoms and enhancing functionality. 2 Structured and validated HRQoL instruments offer the potential of providing an objective framework for the longitudinal evaluation of these important health status measures, which are fundamental to the management of this chronic disease. Several disease-specific HRQoL instruments have been developed over the past 2 decades to better understand and quantify how COPD affects patients' lives, and to evaluate the effectiveness of treatments designed to manage this often fatal disease. 2±15 Of these, the Chronic Respiratory Disease Questionnaire (CRQ) has consistently provided the most responsive measurements of change in individual patients' HRQoL management. 16±20 In an effort to understand the changes over time that this instrument captures among patients with chronic airway limitations, the developers defined minimal, moderate, and large differences in the CRQ domains. 21 They defined a minimal clinically important difference (MCID) as the smallest difference in a score of a domain of interest that patients perceive to be beneficial and that would mandate, in the absence of troublesome side effects and excessive costs, a change in the patient's management. (p. 408)
Their research design, consisting of an evaluation of the mean domain change within patients anchored on a global assessment of change and a consensus panel of persons familiar with the patients and the instrument, has been replicated by other investigators seeking to understand meaningful intra-individual differences in HRQoL measures.
22±24
This approach, however, has been criticized on several grounds. The patients' global change ratings were completely subjective, were based on a single item, and were not evaluated with regard to test-retest reliability. 25 In addition, the change levels (minimal, moderate, and large)
were defined somewhat arbitrarily and were based upon an untested assumption that increases and decreases were symmetric, i.e., that a given level of change (e.g., minimal) can be identified by the same benchmark whether it is an improvement or a decline. Other investigators have questioned the small developmental samples in this study that required the pooling of COPD patients measured by the CRQ with cardiac patients involved in a similar evaluation who were measured by the Chronic Heart Failure Questionnaire (CHQ). 26, 27 The results from the original CRQ consensus panel have also been challenged. 26, 27 That panel was from a single clinical site, and the published report did not specify the clinical expertise of panel members. In addition, although the CRQ and CHQ instruments are very similar, the results of the consensus panel also involved pooling changes for both the CRQ and CHQ instruments, which assumes that the same change standards should apply to both instruments and both conditions. Recognizing that there were few``clinical'' aspects to this investigation, the developers of the CRQ change standards subsequently substituted the term``minimal important difference'' for the MCID. 28 Despite the many problematic aspects of the CRQ developmental studies, quantifying clinically important increments in HRQoL measures remains an important issue if these instruments are to be routinely and comfortably used by clinicians to enhance their estimation of a COPD patient's disease severity and assessment of the impact on patient care, and ultimately, to improve patient outcomes. Other investigations that tie HRQoL change scores to external evaluations (anchors) of change, and distribution-based studies that use statistical parameters (like the standard deviation) to evaluate individual and group HRQoL changes have appeared in the literature as researchers and practitioners continued to seek standards for assessing important HRQoL differences in COPDspecific measures. 29 This report attempts to fill these gaps in the literature by detailing the highly structured process and the resulting clinically important change thresholds for COPD patients established by an expert panel of physicians for the CRQ and the SF-36. Using the consensus development process advanced by researchers at the RAND Corporation, we empanelled 9 physicians from across North America. Each participating physician was experienced in using the CRQ or the SF-36, in addition to other HRQoL questionnaires. The goal of the panel was to reach consensus on how much change in each domain of these 2 instruments signified small, moderate, and large clinically important differences (CIDs), either improvements or declines, for individuals with COPD.
METHODS
The consensus development conference process, originally developed by the RAND Corporation to evaluate the appropriateness of medical and surgical techniques, synthesizes the opinions of experts with the available evidence to provide detailed assessments. 33 Since its publication, this method of integrating existing knowledge to establish practice standards has been applied to healthrelated concerns beyond appropriateness, such as the development of indication guidelines of alcohol abuse in older persons 34 and the establishment of priorities for quality of care studies. 35 The consensus development conference process 36 can be described using its 4 procedural stages: context, which encompasses the issue that the conference will explore; panel composition, where the qualifications of appropriate panelists are determined and panelists are selected to comprise a balanced board; the pre-panel process, where background information and relevant literature research are prepared for presentation to the panelists; and, finally, the panel meeting, where, through a variety of ways, all panelists convene and seek to achieve an a priori defined level of consensus among participants on the context issue.
Context
The context for the panel conference was to determine the amounts of change in the domain scores of the CRQ and SF-36, Version 2.0, that reflect small, moderate, and large clinically important improvements and declines in HRQoL among COPD patients. This context was communicated to the panelists, although no specific definition of`c linically important change'' was provided.
Panel Composition
We began the panel selection process in October 1999 by conducting literature searches of the MEDLINE database (January 1995 to October 1999) and collecting literature pertinent to HRQoL among patients with COPD. We used the search term for``lung disease, obstructive'' as both a key word and as text words (obstructive pulmonary disease), and intersected those results with text words that identified each of the HRQoL instruments (CRQ or the SF-36). In order to cast a wider net, the disease term was also intersected with the key word``quality of life.'' We then reviewed all of the resulting articles from these searches on the basis of the following criteria. First, the article needed to represent an original longitudinal investigation of HRQoL change using at least 1 of the appropriate HRQoL measures. Second, articles using the CRQ or the SF-36 needed to measure and report changes in all 4 CRQ Using these criteria, we identified 10 articles. Each member of the panel planning committee (chaired by WMT, and including KWW, KK, ANB, and FDW) reviewed the articles, and determined that all of the 33 physician authors from these 10 articles were suitable to serve as panel members. We then sent (via overnight express delivery) each of the potential panelists a letter that solicited their interest in serving on the panel of expert physicians. We further explained that because each panel must ultimately represent a balance between generalists and specialists, geographic diversity, etc., panel members would be selected from among those who expressed interest in participating. We also included an overview of the study, and requested a list of available dates for attending a panel meeting from those physicians interested in participating. Of the 33 potential panelists, 13 indicated availability and interest in being considered further. One potential panelist nominated a colleague who had several relevant publications just outside the original search window. After review by the panel planning committee, this potential panelist substitution was allowed. From these 14 physicians, the need for balance between generalists and specialists, and for geographic diversity, as well as the logistics of availability for meeting on a single date, led to the final selection of 9 panelists (see acknowledgments) by the planning committee. From these panelists, the chair of the panel planning committee selected the panel's chair (SDF).
Pre-panel Process
Approximately 2 months prior to the panel meeting, we initiated the pre-panel process with the chosen panelists by sending pertinent literature related to HRQoL change measured by the CRQ and the SF-36 among COPD patients, as well as the instruments themselves (the CRQ and the SF-36, Version 2.0). In an attempt to provide realistic evidence related to clinically important changes in individual patients' HRQoL, we also included several retrospective change scenarios developed from COPD outpatients enrolled in a previous longitudinal study of HRQoL. 26 To construct these patient scenarios, we identified 15 patients enrolled in the above-mentioned study 26 who had 2 clinical encounters (office visits, etc.) on the day or very close to the day of their HRQoL telephone interviews, which were scheduled every 6 months regardless of any clinic visit schedules. After examining the HRQoL scores of these patients, we focused on the 9 patients who had changes in most of their HRQoL domains between visits. For these patients, we pulled the medical charts to obtain the visitspecific discharge notes and orders. Complete medical chart data were found in a timely manner for 6 of these patients. Blinded to the patients' HRQoL data, 2 physicians (WMT and KK) reviewed these 6 medical charts and reported lung disease and comorbid diagnoses, current medications, history, physical examination results, treatment plans and changes in treatment for the 2 clinical encounters in questions for each patient. The clinical report for each patient was presented to the panelists at the beginning of the patient scenario, followed by the patient's CRQ and SF-36 domain scores from the telephone interviews on or near the date of the clinical encounters, as well as the change score for each domain. The 6 retrospective change scenarios are presented in Appendix A, available on the Journal's web page (http://www.blackwellscience.com/jgi). Employing a 2-round Delphi process, 37 panelists completed 2 tasks using these materials in Round 1. First, they read and reviewed the selected literature and the actual patient scenarios and indicated what they believed constitutes a minimal, moderate, or large clinically important change (improvement or decline) in HRQoL within each domain of the CRQ and the SF-36. Second, they indicated additional pertinent literature that should be included in the next mailing to all panelists. We compiled the results and comments from Round 1 and obtained copies of the requested literature. These materials were distributed in a second mailing to the panel, and provided an opportunity for each panelist to survey the field with regard to the other panelists' opinions on the context issues. After reviewing the Round 2 information, panelists again completed the task of reviewing the newly identified literature and indicating what they believed constitutes a minimal, moderate, or large clinically important change (improvement or decline) in each domain of both HRQoL instruments. Prior to the panel meeting, we sent the results from Round 2 to the panelists using the same process.
Panel Meeting
At a 4-hour meeting, the panelists focused on achieving consensus on clinically important change thresholds for small, moderate, and large individual improvement and decline in the domains of the CRQ and the SF-36, Version 2.0. Although panelists did attempt to achieve unanimity, the a priori criterion for consensus required only a substantial majority (all but 2 panelists). Both audiotapes and videotapes of the meeting were made and subsequently transcribed. The meeting transcripts were presented to the panel chair, who drafted a consensus report for circulation to all panelists. Panel members then iteratively modified this report until all accepted it as an accurate reflection of the panel's conclusions. The panel conference activities received approval from all appropriate Institutional Review Boards.
RESULTS
The panel met in St. Louis, Missouri on June 15, 2000 after reviewing the results of the 2 Delphi rounds of the prepanel process. Initially, each panelist briefly described his/ her method for determining CIDs for the CRQ. Although most of the panel members assigned similar values to small, moderate, and large changes, there was some variation in their approaches. Their methods fell into 4 camps: 1) the consideration of patient score change data from their own successful respiratory rehabilitation or pharmaceutical interventions; 2) the application of a proportion (e.g., 20%, 40%, and 60%) to each measure's scoring range; 3) a triangulation of results from 3 previous investigations, 21, 26, 28 where minimal change standards for the CRQ converged at nearly the same levels, and then an extraction of these CRQ results to the SF-36; and 4) the application of Cohen's effect size criteria (0.2, 0.5, and 0.8 standard deviations) for evaluating change. The panel then discussed the course they would adopt for assigning final values to each scale. It was unanimously agreed that the CIDs should be symmetric so that positive and negative changes in the same category (e.g., a small decline or a small improvement) would uniformly be of the same magnitude. It was also unanimously agreed that the increases from small to moderate and from moderate to large should be arithmetic, increasing incrementally by the value of a small change. Furthermore, there was general agreement that it was usually best to err on the side of accepting a smaller change as important rather than overlooking an important change in an individual patient. Finally, it was noted that, ideally, the smallest CID should be greater than the intrinsic variability of a domain or scale.
The group began with the dyspnea dimension of the CRQ. They first reviewed the results of their earlier Delphi rounds and information about the statistical properties of the scale in several samples of COPD patients. They also considered the number of items in the domain (i.e., 5) and the number of those items that would have to change by the minimal amount to be considered clinically important. For all CRQ dimensions, 1 point represents the smallest possible score change on any item in the domain. The panel came to adopt the term state change to describe this minimal movement on a single item. After extensive discussion, the panel reached a consensus for the dyspnea dimension: 3 points represented a small CID, 6 points a moderate CID, and 9 points a large CID. The group then proceeded to apply this process to determine the CIDs for the remaining 3 dimensions of the CRQ (Table 1) . For several of the dimensions, however, the panel deliberated with considerable discussion before achieving a consensus.
The Table 2 . Small changes on the SF-36, Version 2.0 scale scores ranged from 8.3 to 12.5, while moderate changes ranged from 16 to 25 and large changes ranged from 25 to 37.5 points on these 0±100 scales.
DISCUSSION
Standards for establishing the amount of change over time needed in a HRQoL measure in order for that change to be considered important or relevant can be determined empirically by within-person change studies. However, such anchor-based methods incorporate only the patients' perspectives of important change, and do not reflect an informed clinical evaluation of HRQoL change. As stated in 1998 by Carolyn Clancy and John Eisenberg in Science,`A dditional work to enhance the interpretability of outcome measures, particularly in terms of clinical significance, is needed to increase the usefulness of these tools. Clinicians are unlikely to use patient-reported outcome measures routinely unless the reports are as familiar to them as blood pressure and other physiological measures.'' (p. 256) 38 As a first step in developing standards for``clinically important differences'' for the diseasespecific CRQ and the generic SF-36, Version 2.0 when used in patients with COPD, we assembled a 9-person expert panel of North American physicians familiar with the use of at least 1 of these HRQoL measures among patients with COPD. Using 2 rounds of the Delphi process, 1 in-person meeting, and an iterative improvement process for circulating and correcting the final report of the panel meeting by the respective panel chairman, CIDs from an expert panel were established for each HRQoL measure. Our panel's levels for detecting CIDs on the CRQ were on average slightly higher than previously investigated change levels for the CRQ based on patient-perceived differences. In the 1989 study by Jaeschke et al., an average change per item of 0.5 was considered a minimal (small) important difference in the dyspnea, fatigue, and emotional function dimensions of the CRQ. 21 When multiplied by the number of items in each dimension, this equates to small CID thresholds of 2.5, 2.0, and 3.5, respectively, in dyspnea, fatigue, and emotional function. In contrast, this expert panel reached consensus on small CID thresholds of 3, 2, and 5, respectively, which are attainable integer change scores for individuals. However, similar to the Jaeschke et al. results, the panel incremented these small CIDs by multipliers of 2 and 3 to set the moderate and large CID standards. 21 The panel also set CID levels for the mastery dimension, which had been excluded from the Jaeschke et al. investigation because of the lack of a similar domain in the simultaneously studied CHQ. When we applied these new standards for the evaluation of CRQ dimensional change scores among 393 outpatients with COPD in the a previous HRQoL Study 26 and compared the classifications (no change, small, moderate, or large) with the cutpoints reported by Jaeschke et al., 51 (13%) of these outpatients were classified differently in the dyspnea dimension, while 107 (27%) had different classifications in the emotional function domain. Determining CIDs for the SF-36 scales proved to be a more challenging task for the panel that was complicated by the instrument's differing scale increments (i.e., the numeric value of a state change). Nonetheless, the panel adopted an informed and practical approach by considering the possible score changes that can result on each SF-36 scale (noted in the state change column of Table 2 ). They then compared these state changes to their own experiences with COPD patients, as well as to distributionbased methods that have been used to interpret HRQoL change, and agreed on the reported levels. The magnitude of these change levels (!8.3 points) should shed light on the widely held but poorly substantiated belief that a 3-to 5-point change on an SF-36 scale indicates a clinically important intra-individual difference. This belief stems from a 1989 report of SF-20 39 cross-sectional data collected from a large study of patients with and without chronic health conditions. 32 In those data, the predicted average on the health perceptions scale (mean = 69.1) for the hypertension group (N = 2,708) was 3.5 points lower and statistically different (P < .001) from the respective scale average (mean = 72.6) for those participants with no self-reported chronic conditions (N = 2,595), after controlling for age, gender, education, and income. Thè`s ignificance'' of this cross-sectional difference, however, was driven by very large sample sizes, and was not determined using data that assessed patient change over time.
It is important to note that we did not provide definitions of clinically important differences or the magnitudes of change (small, moderate, and large) to the panelists. Instead, we hoped that the physician panelists, each experienced in the use of these measures, would come to their own understanding of these terms. Although prior work by Jaeschke et al. attempted to define a minimally clinically important difference, that definition has some shortcomings. 21 First, it directly speaks to score differences that are perceived beneficial to the patient, but does not address detrimental changes. Even if one considers an appropriate interpretation of this definition to include avoiding deterioration as a benefit, the patient with no perceived change is not properly recognized or classified. Second, even when the clinician and the patient agree that an important improvement or decline in HRQoL has occurred, this may not necessarily``mandate a change in the patient's management,'' especially if such a change would be detrimental to the care of the patient, 24 or if all clinical options have been exhausted. We were pleased that our panelists, who are experienced in both providing clinical care for and performing research among patients with COPD as well as being experienced in the use of these HRQoL measures, came to their own interpretations of CIDs and the magnitude of those differences. Moreover, their interpretations converged when the panelists quantified these changes in the CRQ and SF-36 domains. Despite the extensive efforts we undertook to obtain reliable and accurate results in this study, potential shortcomings remain and warrant mention. First, we employed only a single panel of physicians. Studies by RAND with several physician panels demonstrated substantial heterogeneity in their assessments of the appropriateness of different medical procedures. 40 However, the panel employed in the present study was comprised only of physicians who had substantial clinical and research experience with the task at hand, while this was not the case in the RAND studies. Second, it is possible that panelists were biased by the results of prior research and might have arrived at different conclusions had they been unfamiliar with that literature. Using experienced physicians, such exposure to earlier studies was unavoidable. Moreover, the widely varying approaches employed by different panelists at the start of the process strongly suggest that few were biased in this fashion. Third, when there are limited clinical data, clinicians may require a greater change in the data that are available before judging that a clinical change has occurred. That is, when clinical information is minimal, the recognition of clinical change will be conservative. And finally, although we made every effort to maintain the integrity of the consensus process, the possibility remains that some members of the panel succumbed to well-known influences of group process. 41 Coupled with this, there was no measure of the reliability of the panelists' judgments about clinically significant change. While the expert panel process is designed to add validity to such judgments, we cannot report a measure of actual agreement. Establishing clinical change standards for HRQoL measures requires both clinical insight into the etiology, symptoms, and progression of the disease, as well as patient insight related to living with the chronic disease. Using the RAND consensus method for integrating the expert physicians' opinions with the available evidence, our results provide clinicians with usable standards for assessing change in the HRQoL of COPD patients seen in clinical practice, and in doing so, enhance their estimation of a COPD patient's disease severity and assessment of impact on patient care, and ultimately, improve patient outcomes. These results also provide COPD researchers with standards for evaluating the results of HRQoL research investigations among patients with COPD. However, these panel results reflect the judgment of only 1 group of physician experts. We must now compare the expert physicians' estimates of important change to the change estimates of patients with COPD. Moreover, additional insight on CIDs can be obtained from the physicians who routinely treat these COPD patients and who can directly observe their HRQoL changes. 42 Contrasting these physicians' assessments of HRQoL changes with those of their COPD patients will further elucidate how clinically important differences and patient-perceived differences in HRQoL compare. History: Patient seen in Medicine Clinic one month previously for runny nose, productive cough with yellow sputum, and dyspnea on exertion. Oxygen saturation at that time was 93% (FIO 2 not specified). On previous visit, she had end-expiratory wheezes without crackles. Patient was given the diagnosis at that visit of bronchitis with COPD exacerbation, and treated with amoxicillin, pseudoephedrine, and albuterol inhaler prn. Also scheduled pulmonary function studies. On 4/11/95, patient complained of swelling in her abdomen and feeling a``knot'' in her right lower quadrant. She had a history of cervical and breast cancer. 
